Work with us

Are you a bladder cancer researcher?

Work with us on a project combining multimodal data and AI to better understand MIBC patient subtyping and treatment response.

Are you interested in exploring these questions?

We are looking for bladder cancer researchers with patient data cohorts to work with us on a project to better understand MIBC patient subtying and treatment response.

The population of interest is adult patients with non-metastatic MIBC, treated with the SoC: neo adjuvant chemotherapy (platinum based therapy or non platinum based therapy) and surgery (cystectomy).

If the patient is not eligible for surgery, those treated with chemotherapy (platinum based therapy or non platinum based therapy) may be included.

Owkin can help you:

RNA ready

Access cutting edge tech, such as generating RNA sequencing data from tumor samples

AI ready

Finance and support the collection, curation and enrichment of datasets to make them AI ready

AI ready datasets

Use these newly generated AI ready datasets to perform your own research after the project

Data generation

Simplify your data generation processes, make datasets interoperable and promote collaborations with other PIs

Unlock opportunities

Unlock new project-independent funding opportunities

About the project

Complete response to chemotherapy is observed in only 20-40% of MIBC patients. Although emerging therapies such as the use of immune checkpoint inhibitors (CPI) have shown some promising results, 50-77% of patients do not respond to CPI and the underlying mechanisms are poorly understood.

Owkin scientists are using the latest AI techniques to explore critical questions in this field. These include the prediction of resistance to SoC (chemo+ cystectomy) in MIBC and identifying new targets in this subgroup. Overall, for bladder cancer AI methodologies have been developed to answer medical needs but very few models have used a multimodal approach using H&E slides and genomics.

Considering that histology is the standard examination to assess the staging and grading of bladder cancer, and genomics allows a better definition of personalized treatment in oncology, we believe a multimodal approach could facilitate a better understanding of the disease’s treatment and mechanism.

This project will use a broad range of multimodal data to better understand the underlying cellular mechanisms driving the subtype of patients non-metastatic MIBC, including:

  • Clinical (demographics, history of treatment, and routine biological data at diagnosis (MIBC) and/or before the start I/O
  • Treatment and follow up data
  • Imaging: histopathology (HE) and IHC from transurethral bladder
  • Resection tumor (TURBT) for and from pieces of cystectomy (both when available) biopsy for patients with MIBC
  • Transcriptomics data: RNAseq and/or scRNAseq from tumors samples if available (can be generated from FFPE of tumor)
  • Genomics data: WES if available